



Europäisches Patentamt

European Patent Office

Office européen des brevets



7  
⑪ Publication number : **0 441 765 A1**

⑫

## EUROPEAN PATENT APPLICATION

⑬ Application number : **91870022.0**

⑮ Int. Cl.<sup>5</sup> : **C07C 59/125, C07C 323/12,**  
**C12P 21/00**

⑭ Date of filing : **08.02.91**

⑯ Priority : **09.02.90 US 478298**

⑰ Date of publication of application :  
**14.08.91 Bulletin 91/33**

⑲ Designated Contracting States :  
**AT BE CH DE DK ES FR GB GR IT LI LU NL SE**

⑳ Applicant : **WASHINGTON UNIVERSITY**  
1 Brookings Drive  
St. Louis, Missouri 63131 (US)

㉑ Inventor : **Heuckeroth, Robert Otto**  
4221 Flad Avenue  
St Louis, Missouri 63110 (US)  
Inventor : **Adams, Steven Paul**  
77 Ridge Field Court  
St. Charles, Missouri 63303 (US)  
Inventor : **Gordon, Jeffrey Ivan**  
12 Stacey Drive  
Olivette, Missouri 63132 (US)  
Inventor : **Gokel, George William**  
15560 Southwest 54 Street  
Miami, Florida 33185 (US)

㉒ Representative : **Ernst, Hubert et al**  
**Monsanto Services International S.A., Patent**  
**Department, Avenue de Tervuren 270-272,**  
**Letter Box No. 21**  
**B-1150 Brussels (BE)**

㉓ Novel fatty acid analog enzyme substrates.

㉔ Novel diheteroatom-substituted fatty acid analog substrates of myristoylating enzymes are provided which contain oxygen and/or sulfur in place of two methylene groups in carbon positions from 3 to 13 in the fatty acid chain of a C<sub>13</sub> - C<sub>14</sub> fatty acid analog or alkyl ester thereof in which said oxygen or sulfur atoms are separated by at least one methylene group.

EP 0 441 765 A1

## NOVEL FATTY ACID ANALOG ENZYME SUBSTRATES

Background of the Invention


5 This invention relates to novel fatty acid analog substrates of myristoylating enzymes and, more particularly, to diheteroatom-substituted fatty acid analogs in which the heteroatoms are oxygen and/or sulfur and which are useful in the fatty acid acylation of peptides and proteins.

10 Fatty acid acylation of specific eukaryotic proteins is a well established process which can conveniently be divided into two categories. On the one hand, palmitate ( $C_{16}$ ) is linked to membrane proteins via ester or thioester linkage post-translationally.

15 On the other hand, it is known that myristate ( $C_{14}$ ) becomes covalently bound to soluble and membrane proteins via amide linkage early in the protein biosynthetic pathway. In the N-myristoylated proteins, amino-terminal glycine residues are known to be the site of acylation.

20 A variety of viral and cellular proteins have been shown to be thus modified by the covalent attachment of myristate linked through an amide bound to glycine at their amino termini. An example of a most thoroughly studied myristoylated protein is the transforming protein of Rous sarcoma virus, p60<sup>src</sup>.

The myristoylation reaction can be represented as follows :



Further background information on the above protein fatty acid acylation can be had by reference to the following series of articles by scientists associated with the Washington University School of Medicine :

30 Towler and Glaser, Biochemistry 25, 878-84 (1986) ;

Towler and Glaser, Proc. Natl. Acad. Sci. USA 83, 2812-2816 (1986) ;

Towler et al., Proc. Natl. Acad. Sci. USA 84, 2708-2712 (1987) ;

Towler et al., J. Biol. Chem. 262, 1030-1036 (1987) ;

Towler et al., Ann. Rev. Biochem. 57, 69-99 (1988) ;

35 Heuckerth et al., Proc. Natl. Acad. Sci. USA 85, 8795-8799 (1988) ; and

Heuckerth and Gordon, Proc. Natl. Acad. Sci. USA 86, 5262-5266 (1989).

Unique synthetic peptides having relatively short amino acid sequences which are useful as substrates of myristoylating enzymes are described in U.S. Pat. Nos. 4,740,588 and 4,778,878. Examples of such peptides are

40 Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg and

Gly-Asn-Ala-Ala-Ser-Tyr-Arg-Arg.

Certain other unique synthetic peptides are inhibitors of myristoylating enzymes as described in U.S. Pat. Nos. 4,709,012 and 4,778,877.

45 Brief Description of the Invention

In accordance with the present invention, novel fatty acid analog substrates for myristoylating enzymes are provided. These novel compounds are diheteroatom-substituted fatty acid analogs in which the heteroatoms are oxygen and/or sulfur and which are useful in the fatty acid acylation of proteins. They contain 50 two atoms of oxygen and/or sulfur in place of two methylene ( $-\text{CH}_2-$ ) groups in carbon positions from 3 to 13 in the fatty acid chain of a  $C_{13}$ - $C_{14}$  fatty acid or alkyl ester thereof. The carboxyl carbon atom is defined herein as number 1 based on conventional nomenclature. The heteroatoms are preferably separated by about 2 to 5 methylene groups in these fatty acid analogs. Preferred alkyl esters of the fatty acid analogs have from 1 to 6 carbon atoms in the alkyl group.

55 These novel substrate compounds are useful for studying the regulation of enzyme action in fatty acid acylation and the role of N-myristoylation in protein function. They can serve as synthetic substrates for the N-myris-

toylating enzymes in sources such as yeasts, fungi, wheat germ lysates and mammalian cells. These novel compounds differ in hydrophobicity from myristic acid while maintaining approximately the same chain length.

5 Thus, when incorporated into myristoylproteins, they should alter the acylprotein's subsequent interactions with membranes or with other proteins. They also have potential use as antiviral, antifungal and antineoplastic agents.

Illustrative examples of the novel diheteroatom-substituted fatty acid analog substrate compounds of this invention are :

- 10 A. 6,12-Dithiatetradecanoic acid  $\text{CH}_3\text{CH}_2\text{S}(\text{CH}_2)_6\text{S}(\text{CH}_2)_4\text{COOH}$
- B. 6,12-Dioxatetradecanoic acid  $\text{CH}_3\text{CH}_2\text{O}(\text{CH}_2)_5\text{O}(\text{CH}_2)_4\text{COOH}$
- C. 7,10-Dithiatetradecanoic acid  $\text{CH}_3(\text{CH}_2)_3\text{S}(\text{CH}_2)_2\text{S}(\text{CH}_2)_5\text{COOH}$
- D. 7,10-Dioxatetradecanoic acid  $\text{CH}_3(\text{CH}_2)_3\text{O}(\text{CH}_2)_2\text{O}(\text{CH}_2)_6\text{COOH}$
- E. 9,12-Dioxatetradecanoic acid  $\text{CH}_3\text{CH}_2\text{O}(\text{CH}_2)_2\text{O}(\text{CH}_2)_7\text{COOH}$
- 15 F. 9,12-Dithiatetradecanoic acid  $\text{CH}_3\text{CH}_2\text{S}(\text{CH}_2)_2\text{S}(\text{CH}_2)_7\text{COOH}$
- G. 9-Oxa,12-thiatetradecanoic acid  $\text{CH}_3\text{CH}_2\text{S}(\text{CH}_2)_2\text{O}(\text{CH}_2)_7\text{COOH}$
- H. 12-Oxa,9-thiatetradecanoic acid  $\text{CH}_3\text{CH}_2\text{O}(\text{CH}_2)_2\text{S}(\text{CH}_2)_7\text{COOH}$
- I. 10,13-Dioxatetradecanoic acid  $\text{CH}_3\text{O}(\text{CH}_2)_2\text{O}(\text{CH}_2)_5\text{COOH}$
- J. 12-Oxa,6-thiatetradecanoic acid  $\text{CH}_3\text{CH}_2\text{O}(\text{CH}_2)_6\text{S}(\text{CH}_2)_4\text{COOH}$

20 These type compounds alternatively can be named by their common fatty acid derivation, e.g. myristic acid. Thus, compound A can also be designated as 6,12-dithiamyristic acid.

#### Detailed Description of the Invention

25 The preparation of many of the diheteroatom-substituted fatty acid analog substrate compounds can be carried out by methods analogous to the preparation of mixed ethers by the Williamson synthesis. Thus, an appropriate  $\omega$ -bromocarboxylic acid can be reacted with an alkoxy alcoholate to produce the dioxy-substituted fatty acid ether. So also, an appropriate  $\omega$ -iodocarboxylate ester can be reacted with an alkylthioalkyl thiol followed by alkaline cleavage of the ester group to produce the dithia-substituted fatty acid ether.

30 Both of the foregoing type reactions preferably are carried out in organic solvent medium at refluxing temperatures until the desired reaction is essentially complete.


Illustratively, 2-butoxyethanol can be reacted with sodium hydride and the resulting alcoholate reacted with 6-bromohexanoic acid to give 7,10-dioxatetradecanoic acid. So also, 2-ethoxyethanol can be reacted with sodium hydride and the resulting alcoholate reacted with 8-bromoocanoic acid to provide 9,12-dioxatetradecanoic acid.

35 To illustrate the preparation of the dithia-substituted fatty acid ethers, 5-ethylthiopentane thiol can be reacted with sodium hydride and the resulting product reacted with ethyl 5-iodovalerate to yield ethyl 6,12-dithiatetradecanoate. The ester group can then be removed by treatment with alkali metal hydroxide, e.g. NaOH, to produce the desired 6,12-dithiatetradecanoic acid.

40 Similarly, other dithia- or dioxy-substituted fatty acid ethers can be made in an analogous manner by selecting appropriate alkyl and fatty acid chain lengths in the reactant compounds to give the desired products.

In the case of the preparation of one of the diheteroatom-substituted fatty acid analogs, namely 6,12-dioxatetradecanoic acid, considerable difficulties were encountered. Thus, the reaction of 5-ethoxypentan-1-ol with a variety of 5-halovalerate alkyl esters afforded ester exchange products rather than the desired products of Williamson ether synthesis. Accordingly, a novel synthesis of the 6,12-dioxatetradecanoic acid was developed as described in Example 5, below. This synthesis can be summarized as follows :

Commercially available 1,5-pentanediol was mono-ethylated (2, 71%) using an equivalent of iodoethane and NaH in THF. The diol was also converted into its mono-tetrahydropyranyl ether (4, 54%) by treatment with dihydropyran and toluenesulfonic acid in methylene chloride [Ngoi et al., *J. Org. Chem.* **54**, 911 (1989)]. Ethoxyalcohol 2 was tosylated (pyridine, TsCl, 0°C) in 40% yield to afford oily 3. The low yield reflects the need to distill this reactive ether. Tosylate 3 was then allowed to react with mono-THP alcohol 4 (NaH, THF, reflux, 24h) to afford, after deprotection, [Corey et al., *J. Am. Chem. Soc.* **91**, 4318 (1969), the diether alcohol, 5, in 37% yield. Oxidation using Kiliani reagent ( $\text{Na}_2\text{Cr}_2\text{O}_7\text{--}2\text{H}_2\text{O}/\text{H}_2\text{SO}_4/\text{H}_2\text{O}$ ) [Kiliani and Merk, *Chem. Ber.* **34** 3562 (1901)] afforded 6,12-dioxatetradecanoic acid, 1, in 52% yield as a colorless oil.



5 Although specific methods of preparation of the novel diheteroatom-substituted fatty acid analogs are described herein, it will be understood that the novel compounds of this invention are not limited to any specific method of preparation.

10 The novel diheteroatom-substituted fatty acid analog compounds of the invention were analyzed in a conventional *in vitro* yeast N-myristoyltransferase (NMT) assay as published by Heuckerth et al., *Proc. Nat'l. Acad. Sci. USA* 85, 8795-8799 (1988). In this assay, the test compounds are first converted to their respective fatty acyl CoA derivatives and then tested as substrates for the yeast NMT. In these assays, the reduction in hydrophobicity observed with, respectively, two sulfurs or two oxygens, or one sulfur and one oxygen, for 15 methylene substitutions is generally about twice that observed with a single sulfur or oxygen substitution. Although the diheteroatom-substituted fatty acid analogs are active substrates of the myristoylation reaction, kinetic analysis of these compounds indicated that they are less effective than the single sulfur or oxygen substituted analogs by such analysis. Thus, the peptide  $K_m$  with 6,12-dithiamyristoyl CoA is 4.4-fold higher than with myristoyl CoA, while the peptide  $K_m$ 's with the double oxygen substituted analogs are 7.5 to 12-fold higher. However when the velocities are considered, the double sulfur-substituted analog appears to produce only a 2-fold reduction in peptide catalytic efficiency ( $V_m/K_m$ ) while 7,10- and 9,12-dioxamyrystoyl CoAs are associated with 5- and 10-fold decreases in peptide catalytic efficiency, respectively.

20 The effective use of the diheteroatom-substituted fatty acid analogs of this invention as substrates of the myristoylation reaction is evident by comparison with a triheteroatom-substituted fatty acid analog, namely 6,9,12-trioxatetradecanoic acid, which exhibited virtually no activity even at a concentration of 100  $\mu$ M.

25 The following examples will further illustrate the invention although it will be appreciated that the invention is not limited to these specific examples.

30 In these examples, the following procedures were used :  $^1$ H NMR were recorded on a Hitachi Perkin-Elmer R-600 spectrometer or on a Varian VXR 400 spectrometer in  $CDCl_3$  containing 1%  $Me_4Si$ . Data are reported in the following order : chemical shift, spin multiplicity (b=broad, s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet), integration, and coupling constant. Infrared spectra were recorded on a Perkin-Elmer 599 infrared spectrometer. All commercially available reagents were used without further purification. Column chromatography was carried out with EM Science  $Al_2O_3$ (80-230 mesh) and Merck Kieselgel 60 (70-230 mesh). Precoated sheets (aluminum oxide 60F<sub>254</sub> neutral Type E or silica gel 60F<sub>254</sub>, 0.2 mm thick) were used for TLC analysis. Combustion analyses were conducted by Atlantic Microlab. Inc., Atlanta, GA.

### EXAMPLE 1

35 Ethyl 6,12-dithiatetradecanoate.  $NaH$  (0.4 g, 8.4 mmol) was washed with hexanes and then suspended in dry THF (55 mL). 5-Ethylthiopentanethiol (8 mmol, 73% pure by GC analysis, contaminated by 1,5-bis(ethylthio)pentane, 1.80 g of mixture) in THF (8 mL) was added and stirred for 1 h at room temperature. Ethyl 5-iodovalerate (2.1 g, 8 mmol) in THF (8 mL) was added and the mixture refluxed for 8 h. The solvent was 40 evaporated *in vacuo*, the residue was dissolved in EtOAc (150 mL), washed with water (2 x 50 mL), brine (50 mL), dried ( $Na_2SO_4$ ), chromatographed (silica gel, EtOAc/hexanes 1 :10) and distilled (Kugelrohr) to yield the title compound (1.86 g, 80%) as a colorless oil (bp 147-149°C/0.2 torr). IR (neat) : 1740  $cm^{-1}$ .  $^1$ H-NMR : 1.25 (t, 6H) ; 1.50 (quintet, 2H) ; 1.54-1.67 (m, 6H) ; 1.73 quintet, 2H) ; 2.32 (t, 2H) ; 2.46-2.57 (m, 8H) ; and 4.12 (q, 2H). Anal. Calcd for  $C_{14}H_{28}S_2O_2$  : C, 57.49 ; H, 9.65%. Found : C, 57.36 ; H, 9.59%.

### EXAMPLE 2

45 6,12-Dithiatetradecanoic acid. Sodium hydroxide (1 M, 6.2 mL, 6.2 mmol) was added to a solution of ethyl 6,12-dithiatetradecanoate (0.9 g, 3.1 mmol) in MeOH (15 mL). After stirring for 4 hours, water (20 mL) was added and the reaction mixture was acidified (pH 1, HCl) extracted with EtOAc (2 x 100 mL), and the organic phase was washed with water (20 mL), brine (20 mL), and then dried ( $Na_2SO_4$ ). The product crystallized from n-hexane to yield the title compound as a white solid (0.77 g, 95%, mp 49.5-50.0°C). IR : 3000, 1720  $cm^{-1}$ ;  $^1$ H NMR, 1.23 (t, 3H), 1.49 (quintet, 2H), 1.56-1.68 (m, 6H), 1.74 (quintet, 2H), 2.38 (t, 2H), 2.51 (t, 2H), 2.53 (t, 4H), 2.54 (q, 2H), and 10.45 (b, 1H). Anal. Calcd for  $C_{12}H_{24}S_2O_2$  : C, 54.50 ; H, 9.15%. Found : C, 54.59 ; H, 9.21%.

### EXAMPLE 3

55 7,10-Dioxatetradecanoic acid.  $NaH$  (2.2 g, 0.045 mol) was allowed to react with 2-butoxyethanol (50 mL) during 1 h. 6-Bromohexanoic acid (4.2 g, 0.0215 mol) was added, the mixture was heated at reflux for 24 h,

5 cooled, and the solvent was removed *in vacuo*. The residue was dissolved in ether (50 mL), washed with water (3 x 40 mL), the aqueous phase was acidified (pH 1.0, 6 M HCl), washed with ether, and the solvent removed *in vacuo*. The yellow oil was chromatographed (silica gel, 10-30% Et<sub>2</sub>O/CH<sub>2</sub>Cl<sub>2</sub>) and distilled (Kugelrohr) to yield the title product (2.0 g, 50%, bp 120°C/0.02 torr). IR : 1740 cm<sup>-1</sup>. <sup>1</sup>H NMR : 0.98 (t, 3H), 1.4 (m, 4H) 1.6 (m, 6H), 2.4 (t, 2H), 3.4 (t, 4H), 3.6 (s, 4H). Anal. Calcd for C<sub>12</sub>H<sub>24</sub>O<sub>4</sub> : C, 62.04 ; H, 10.41%. Found C, 61.99 ; H, 10.47%

**10      EXAMPLE 4**

**9,12-Dioxatetradecanoic acid.** NaH (2.4 g, 0.05 mol) was allowed to react with 2-ethoxyethanol (50 mL) during 30 min. 8-Bromoocanoic acid (4.8 g, 0.021 mol) was added, the solution heated at reflux for 24 h, cooled, and the solvent removed *in vacuo*. The residue was dissolved in ether, washed with water, the aqueous phase acidified (pH 1, HCl), and washed again with ether. The organic phase was dried ( $\text{MgSO}_4$ ), the solvent removed *in vacuo*, and the residue chromatographed (silica gel, 10-25%  $\text{Et}_2\text{O}/\text{CH}_2\text{Cl}_2$ ), and distilled (Kugelrohr) to afford the title compound (0.4 g, 8%) as a yellow oil (bp 232°C/0.02 torr). IR : 1750  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR : 1.3 (t, 3H) ; 1.35 (bs, 6H) ; 1.6 (m, 4H) ; 3.5 (m, 8H). Anal. Calcd for  $\text{C}_{12}\text{H}_{24}\text{O}_4$  : C, 62.07 ; H, 10.41%. Found : C, 61.95 ; H, 10.46%.

20 EXAMPLE 6

8

**25 5-Ethoxypentan-1-ol (2).** NaH (4.2 g, 0.11 mol) was washed with hexane and then suspended in dry THF (400 mL). Pentane-1,5-diol (10.4 g, 0.1 mol) in THF (50 mL) was added and stirred for 1 h at room temperature. Iodoethane (17.2 g, 0.11 mol) in THF (50 mL) was added and the mixture was refluxed for 48 h. After evaporation of the solvent, the residue was dissolved in EtOAc (300 mL). The organic phase was washed with water (2 x 50 mL), brine (50 mL), and dried ( $\text{Na}_2\text{SO}_4$ ). The residue was purified by column chromatography on alumina with 10% 2-propanol in hexane, and then Kugelrohr distillation to give the title product (2) (9.4 g, 71%); bp 45–46°C/0.005 torr; IR(neat): 3400 (broad) and 1115  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR: 1.22 (t, 3H,  $J$ =6.8 Hz), 1.42 (m, 2H), 1.56 (m, 4H), 3.43 (t, 4H,  $J$ =5.8 Hz), 3.48 (q, 2H,  $J$ =6.8 Hz), and 3.58 ppm (b s, 1H).

B.

**35** Synthesis of 6,12-dioxamyristic acid, 5-Oxaoctyl p-toluenesulfonate (3). Compound (2) (3.3g, 0.025 mol) was dissolved in pyridine (25 mL) and then cooled to 0°C. To this solution was added p-toluenesulfonyl chloride (5.7 g, 0.03 mol) with vigorous stirring. After 2h, the reaction mixture was stirred at room temperature for another 5h, and then poured into ice. The aqueous solution was extracted with EtOAc (150 mL). The organic phase was washed with water (50 mL), brine (50 mL), and dried ( $\text{Na}_2\text{SO}_4$ ). The residual oil was purified by Kugelrohr distillation to give the title product (3) (3 g, 40%) ; bp 128-134°C/0.08 torr, IR(neat) : 1355 and 1180  $\text{cm}^{-1}$  ;  $^1\text{H}$  NMR : 1.17 (t, 3H,  $J$ =7 Hz), 1.3-1.8 (m, 6H), 2.43 (s, 3H), 3.36 (t, 2H,  $J$ =7 Hz), 3.42 (q, 2H,  $J$ =7 Hz), 4.0 (t, 2H,  $J$ =6 Hz), 7.28 (d, 2H,  $J$  = 8Hz), and 7.76 ppm (d, 2H,  $J$ =6 Hz).

**40**

45 C

**5-(Tetrahydropyranyl)oxypentan-1-ol (4).** To a mixture of pentane-1,5-diol(5.2 g, 0.05 mol) and p-toluenesulfonic acid (0.1g, 0.53 mmol) in  $\text{CH}_2\text{Cl}_2$  (120 mL) was added slowly dihydro-2H-pyran (4.6 g, 0.055 mol) in  $\text{CH}_2\text{Cl}_2$  (30 mL) at 0°C. After stirring for 2 h at 0°C and for another 1 h at room temperature, saturated  $\text{NaHCO}_3$  (50 mL) was added to the reaction mixture. The  $\text{CH}_2\text{Cl}_2$  layer was washed with saturated  $\text{NaHCO}_3$  (50 mL), water (50 mL), and dried ( $\text{MgSO}_4$ ). The residue was purified by column chromatography on silica gel with  $\text{EtOAc} : \text{hexane}$  (1 : 1, v/v) and subsequent Kugelrohr distillation to give the title product (4, 5.1 g, 54%) ; bp 80-85°C/0.1 torr ; IR(neat) : 3450 (broad) and 1135  $\text{cm}^{-1}$  ;  $^1\text{H NMR}$  : 1.3-1.9 (m, 12H), 2.4 (b s, 1H), 3.3-3.9 (m, 6H), and 4.58 ppm (m, 1H).

55

**6,12-Dioxatetradecane-1-ol (6).** The reaction of compound 3 (2.86 g, 0.01 mol) and compound 4 (1.88 g, 0.01 mol) in the presence of NaH (0.4 g, 0.011 mol) in dry THF (70 mL) was carried out in the same manner described above. The crude oil was chromatographed on silica gel to give a mixture (2.4 g) of the starting

material (3) and compound (5) (40 :60). To this mixture in MeOH (50 mL) was added p-toluenesulfonic acid (28 mg), and the reaction mixture was stirred for 3 h at room temperature. After evaporation of the solvent, the residue was dissolved in EtOAc (150 mL). The organic phase was washed with 5% NaHCO<sub>3</sub> (2 x 50 mL), water (50 mL), brine (50 mL) and dried (Na<sub>2</sub>SO<sub>4</sub>). The residue was purified by column chromatography on silica gel with EtOAc :hexane (1 :1) and Kugelrohr distillation to give the title product (6, 0.8 g, total yield 37%) ; bp 88-92°C/0.05 torr ; IR(neat) : 3460 (broad) and 1115 cm<sup>-1</sup> ; <sup>1</sup>H NMR : 1.18 (t, 3H, J=7 Hz), 1.3-1.8 (m, 12H), 2.1 (b s, 1H), 3.38 (t, 8H J=6.5 Hz), and 3.43 ppm (q, 2H, J=7 Hz).

10

E

**6,12-Dioxatetradecanoic acid (1).** Kiliani reagent [Chem. Ber. 34, 3562 (1901)] was prepared *in situ* by dissolving Na<sub>2</sub>Cr<sub>2</sub>O<sub>7</sub>, 2H<sub>2</sub>O (3 g) in a cold solution of H<sub>2</sub>SO<sub>4</sub> (4 g) and water (13.5 g). To a solution of compound 6 (1.2 g, 5.5 mmol) in AcOH (28 mL) was added Kiliani reagent (20 g) at 0°C. The reaction mixture was stirred for 7 h at room temperature. Water (120 mL) was added to the mixture and then extracted with EtOAc (2 x 100 mL). The organic phase was washed with water (2 x 30 mL) and dried (Na<sub>2</sub>SO<sub>4</sub>). The residual oil was purified by column chromatography on silica gel with CHCl<sub>3</sub> :MeOH (7 :1) and subsequent Kugelrohr distillation to give the title product (1) (0.7 g, 52%) ; bp 128-132 °C/0.1 torr ; IR(neat) : 3000 (broad) and 1730 cm<sup>-1</sup> ; <sup>1</sup>H NMR : 1.23 (t, 3H, J=7.4 Hz), 1.3-1.8 (m, 10H), 2.38 (t, 2H, J=5.4 Hz), 3.3-3.6 (m 8H), and 9.98 ppm (b s, 1H) ; Anal. Calcd for C<sub>12</sub>H<sub>24</sub>O<sub>4</sub> : C, 62.04 ; H, 10.41%. Found : C, 61.95 ; H, 10.43%.

25

Example 610,13-Dioxatetradecanoic acid.

A mixture of 2-methoxyethanol (0.8 mL, 10 mmole), t-butyl-9-bromononanoate (1 g, 3.4 mmole) and tetrabutylammonium hydrogen sulfate (0.25 g, 0.34 mmole) in 50% sodium hydroxide (4 mL) and toluene (2 mL) was stirred vigorously at room temperature for 3 h. The reaction mixture was poured into cold water (20 mL) and products were extracted into ethyl acetate (25 mL). The organic phase was washed with water (3 x 15 mL), dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated under reduced pressure to give an oily residue which was purified by flash chromatography using EtOAc-Hexane (1 :9, v/v) to afford the desired ester (0.4 g, 58%) and unreacted t-butyl bromoester (0.3 g) ; <sup>1</sup>H NMR δ 3.56 (m, 4, -OCH<sub>2</sub>), 3.45 (t, 2, -OCH<sub>2</sub>), 3.39 (s, 3, -OCH<sub>3</sub>), 2.19 (t, 2, -CH<sub>2</sub>), 1.56 (m, 4, -CH<sub>2</sub>), 1.44 (s, 9, t-butyl), 1.3 (m, 8, -CH<sub>2</sub>) ; FAB MS, m/z 295 (M+Li) and 239. This material (0.32 g) was converted to the corresponding carboxylic acid by heating with trifluoroacetic acid (0.3 mL) in THF (3 mL) at 55°C for 4 h.

After removal of the solvent under reduced pressure the residue was purified by flash chromatography using EtOAc-hexane (2 :8, v/v) to give 10,13-dioxatetradecanoic acid as a colorless oil : <sup>1</sup>H NMR δ : 3.57 (m, 4-OCH<sub>2</sub>), 3.45 (t, 2, -OCH<sub>2</sub>), 3.39 (s, 3, -OCH<sub>3</sub>), 2.34 (t, 2, -OCH<sub>2</sub>), 1.6 (m, 4, -CH<sub>2</sub>), 1.3 (m, 8, -CH<sub>2</sub>) ; FAB MS, m/z 239 (M+Li) ; High-resolution FAB MS, m/z 239.1854 (M+Li) requires 239.1839.

30

Example 7

**9-Oxa-12-thiatetradecanoic Acid.** NaH (1.85 g, 0.046 mol) was washed with hexane and then suspended in dry THF (60 mL). 3-Thiapentane-1-ol (4.67 g, 0.04 mol) in THF (20 mL) was added and stirred for 1 h at room temperature. 1,6-Dibromo-hexane (9.76 g, 0.04 mol) in THF (20 mL) was added and the mixture was refluxed for 20 h. After evaporation of the solvent, the residue was dissolved in ethyl acetate (200 mL). The organic phase was washed with water (2 x 50 mL), and dried (Na<sub>2</sub>SO<sub>4</sub>). The crude product was purified by Kugelrohr distillation to give 7-oxa-10-thiadodecyl bromide (3.34 g, 31%) ; bp 48-56°C/0.04 torr ; NMR : 1.25 (3H, t, J=7 Hz), 1.2-1.9 (8H, m), 2.59 (2H, q, J=7 Hz), 2.68 (2H, t, J=7 Hz), and 3.2-3.7 ppm (6H, m).

Sodium metal (0.31 g, 0.014 mol) was dissolved in absolute EtOH (20 mL). To this mixture was added diethyl malonate (2.2 g, 0.014 mol) in EtOH (5 mL) and the above 7-oxa-10-thiadodecyl bromide (3g, 0.011 mol) in EtOH (5 mL) at room temperature. The reaction mixture was refluxed for 5 h. After evaporation of the solvent, the residue was dissolved in ethyl acetate (120 mL). The organic phase was washed with water (2 x 30 mL), brine (30 mL), and dried (Na<sub>2</sub>SO<sub>4</sub>). The crude product was purified by Kugelrohr distillation to give ethyl 2-ethoxycarbonyl-9-oxa-12-thiatetradecanoate (2.3 g, 58%) ; bp 122-128°C/0.04 torr ; NMR : 1.27 (6H, t, J=7 Hz), 3.3-3.7 (5H, m), and 4.17 ppm (4H, q, J=7 Hz), 1.2-1.9 (10H, m), 2.59 (2H, q, J=7 Hz), 2.68 (2H, t, J=7 Hz), 3.1-3.7 (5H, m), and 4.17 ppm (4H, q, J=7 Hz).

A solution of the above ethyl 2-ethoxycarbonyl-9-oxa-12-thiatetradecanoate (2 g, 5.8 mmol) in 20% NaOH

(10 mL) was refluxed for 6 h. The solution was acidified with HCl (pH 2), and extracted with ethyl acetate (120 mL). The organic phase was washed with water (2 x 30 mL), brine (30 mL) and dried ( $\text{Na}_2\text{SO}_4$ ). After evaporation of the solvent, the resulting product was heated on an oil bath at 180 to 200°C for 15 min. The crude product was purified by Kugelrohr distillation to afford the title compound, 9-oxa-12-thiatetradecanoic acid (1.4 g, 98%); bp 121-125°C/0.005 torr; IR(neat) : 3020 (broad) and 1730  $\text{cm}^{-1}$ ; NMR : 1.27 (3H, t,  $J$ =7.7 Hz), 1.34 (6H, m), 1.53-1.68 (4H, m), 2.36 (2H, t,  $J$ =7.1 Hz), 2.58 (2H, q,  $J$ =7.7 Hz), 2.71 (2H, t,  $J$ =7 Hz), 3.45 (2H, t,  $J$ =6.8 Hz), 3.59 (2H, t,  $J$ =7 Hz), and 10.6 ppm (1H, br s); Found : C, 58.11, H, 9.8%. Calcd for  $\text{C}_{12}\text{H}_{24}\text{SO}_4$  : C, 58.03, H, 9.74%.

#### Example 8

Ethyl 9-thia-12-oxatetradecanoate.  $\text{NaH}$  (0.39g, 9.6 mmol) was washed with hexane and then suspended in dry THF (45 mL). 5-Ethoxypentane-1-thiol (8.7 mmol) in THF (8 mL) was added and stirred for 1 h at room temperature. Ethyl 8-iodooctanoate (2.4 g, 8.7 mmol) in THF (7 mL) was added and the mixture was refluxed for 6 h. After evaporation of the solvent, the residue was taken into ethyl acetate (150 mL). The organic phase was washed with water (2 x 50 mL), brine (50 mL), and dried ( $\text{Na}_2\text{SO}_4$ ). The crude product was purified by column chromatography on silica gel with ethyl acetate :hexane (1 :5) and subsequent Kugelrohr distillation to give the title compound, ethyl 9-thia-12-oxatetradecanoate ; yield 52% ; bp 118-120°C/0.15 torr ; NMR : 1.2 (3H, t,  $J$ =7 Hz), 1.25 (3H, t,  $J$ =7 Hz), 1.2-1.8 (10 H, m), 2.28 (2H, t,  $J$ =6.5 Hz), 2.55 (2H, t,  $J$ =7 Hz), 2.67 (2H, t,  $J$ =7 Hz), 3.44 (2H, t,  $J$ =7 Hz), 3.66 (2H, t,  $J$ =7 Hz), and 4.1 ppm (2H, q,  $J$ =7 Hz).

9-Thia-12-oxatetradecanoic Acid.  $\text{NaOH}$  (1M, 24 mL, 24 mmol) was added to a solution of the above ethyl 9-thia-12-oxatetradecanoate. (6.8 mmol) in MeOH (20 mL). After stirring for 7 h, the reaction mixture was acidified with 10% HCl (pH 1) and extracted with ethyl acetate (2 x 100 mL). The organic phase was washed with water (50 mL), brine (50 mL), and dried ( $\text{Na}_2\text{SO}_4$ ). The crude product was recrystallized from hexane to afford the title compound, 9-thia-12-oxatetradecanoic acid ; yield 92% ; bp 134-136°C/0.005 torr ; IR (neat) : 3000 (broad) and 1735  $\text{cm}^{-1}$  NMR : 1.23 (3H, t,  $J$ =7.2 Hz), 1.28-1.46 (6H, m), 1.53-1.68 (4H, m), 2.35 (2H, t,  $J$ =7.3 Hz), 2.54 (2H, t,  $J$ =7.1 Hz), 2.70 (2H, t,  $J$ =7.1 Hz), 3.52 (2H, q,  $J$ =7.2 Hz), 3.60 (2H, t,  $J$ =6.9 Hz), and 8.85 ppm (1H, br s); Found : C, 57.96, H, 9.77%. Calcd for  $\text{C}_{12}\text{H}_{24}\text{SO}_3$  : C, 58.03, H, 9.74%.

#### Example 9

Ethyl 6-thia-12-oxatetradecanoate.  $\text{NaH}$  (0.39g, 9.6 mmol) was washed with hexane and then suspended in dry THF (45 mL). 2-Ethoxyethane-1-thiol (8.7 mmol) in the THF (8 mL) was added and stirred for 1 h at room temperature. Ethyl 8-iodooctanoate (8.7 mmol) in THF (7 mL) was added and the mixture was refluxed for 6 h. After evaporation of the solvent, the residue was taken into ethyl acetate (150 mL). The organic phase was washed with water (2 x 50 mL), brine (50 mL), and dried ( $\text{Na}_2\text{SO}_4$ ). The crude product was purified by column chromatography on silica gel with ethyl acetate :hexane (1 :5) and subsequent Kugelrohr distillation to give the title compound, ethyl 6-thia-12-oxatetradecanoate ; yield 81% ; bp 116-120°C/0.1 torr ; IR(neat) : 1745-1 ; NMR : 1.18 (3H, t,  $J$ =7 Hz), 1.25 (3H, t,  $J$ =7 Hz), 1.45-1.9 (10H, m), 2.2-2.7 (6H, m), 3.45 (2H, q,  $J$ =7 Hz), 3.39 (2H, t,  $J$ =6 Hz), and 4.12 ppm (2H, q,  $J$ =7 Hz).

6-Thia-12-oxatetradecanoic Acid.  $\text{NaOH}$  (1M, 24 mL, 24 mmol) was added to a solution of the above ethyl 6-thia-12-oxatetradecanoate. (6.8 mmol) in MeOH (20 mL). After stirring for 7 h, the reaction mixture was acidified with 10% HCl (pH 1) and extracted with ethyl acetate (2 x 100 mL). The organic phase was washed with water (50 mL), brine (50 mL), and dried ( $\text{Na}_2\text{SO}_4$ ). The crude product was recrystallized from hexane to afford the title compound, 6-thia-12-oxatetradecanoic acid ; yield 82% ; bp 144-146°C/0.01 torr ; IR(neat) : 3000 (broad) and 1730  $\text{cm}^{-1}$  ; NMR : 1.23 (3H, t,  $J$ =7.3 Hz), 1.46 (2H, quint,  $J$ =6.9 Hz), 1.55-1.69 (6H, m), 1.74 (2H, quint,  $J$ =7.3 Hz), 2.37 (2H, t,  $J$ =7.6 Hz), 2.51 (2H, t,  $J$ =7 Hz), 2.53 (2H, t,  $J$ =7 Hz), 3.42 (2H, t,  $J$ =6.9 Hz), 3.48 (2H, q,  $J$ =7.3 Hz), and 10.6 ppm (1H, br s); Found : C, 58.07, H, 9.78%. Calcd for  $\text{C}_{13}\text{H}_{26}\text{SO}_2$  : C, 58.03, H, 9.74%.

#### Example 10

Compounds prepared in the foregoing illustrative specific examples were analyzed in a conventional *in vitro* yeast N-myristoyltransferase (NMT) assay as published by Heuckerth et al., Proc. Natl. Acad. Sci. USA 85, 8795-8799 (1988). In this assay, the test compounds were first converted to their respective fatty acyl CoA derivatives and then tested as substrates for the yeast NMT.

The assay conditions [essentially the same as those reported by Towler and Glaser, Proc. Natl. Acad. Sci. USA 83, 2812-2816 (1986)] were as follows :

1. **Ligase reaction** : 3.3  $\mu$ moles fatty acid, 5 mM ATP and 1 mM CoA were incubated with 15-150 milliunits of CoA ligase (1 unit/ml in 50 mM HEPES, pH 7.3) in a buffer composed of 10 mM TRIS HCl, pH 7.4, 1 mM dithiothreitol, 5  $\mu$ M MgCl<sub>2</sub> and 0.1 mM EGTA, in a total volume of 50  $\mu$ l for 25 minutes at 30°C.

5                   2. **NMT assay** : 50  $\mu$ l of the CoA ligase mixture was added to a 50  $\mu$ l solution of 90  $\mu$ M peptide (GSAA-SARR-NH<sub>2</sub>) in a buffer composed of 10 mM TRIS HCl, pH 7.4, 1 mM dithiothreitol, 0.01 mM EGTA and aprotinin (10  $\mu$ g/ml). 0.4 Unit of yeast N-myristoyltransferase was then added and the reaction mixture was  
10                Incubated at 30°C for 10 minutes. The peptide was radiolabeled with tritium in alanine in position 3. The reaction was quenched with 120  $\mu$ l of TCA-MEOH and 75  $\mu$ l was injected on a reverse phase C18 HPLC column and eluted with a linear gradient of 0-100% acetonitrile over 100 minutes (both water and acetonitrile containing 0.1% trifluoroacetic acid). Radioactivity was assessed with an on line radiomatic detector corrected for quenching.

15                The amount of radioactivity was determined for each diheteroatom-substituted fatty acyl peptide product and then was normalized to the amount of myristoyl peptide produced in an assay run in parallel.

20                The activity of each fatty acid analog was thus expressed as a percentage of the activity exhibited by unsubstituted myristate (control) and recorded in the following Table 1.

TABLE 1

## Substrate Activity of Diheteroatom Fatty Acid Analogs

| 25 | Test<br>Compound | Myristate<br>Analog | Activity<br>(% of Myristate) |
|----|------------------|---------------------|------------------------------|
| 30 | A. Example 2     | 6,12-dithia         | 95%                          |
|    | B. Example 5     | 6,12-dioxa          | 4%                           |
|    | D. Example 3     | 7,10-dioxa          | 6%                           |
|    | E. Example 4     | 9,12-dioxa          | 11%                          |
| 35 | G. Example 7     | 9-oxa-12-thia       | 37%                          |
|    | H. Example 8     | 9-thia-12-oxa       | 61%                          |
|    | I. Example 6     | 10,13-dioxa         | 7%                           |
| 40 | J. Example 9     | 6-thia-12-oxa       | 38%                          |

45                Various other examples will be apparent to the person skilled in the art after reading the present disclosure without departing from the spirit and scope of the invention. All such other examples are included within the scope of the appended claims.

## Claims

50                1. A diheteroatom-substituted fatty acid analog compound having activity as a substrate for myristoylating enzymes/selected from the group consisting of C<sub>13</sub> or C<sub>14</sub> fatty acids or alkyl esters thereof in which two methylene groups normally in carbon positions from 3 to 13 are replaced by oxygen and/or sulfur and in which said oxygen or sulfur atoms are separated by at least one methylene group.

55                2. A compound of Claim 1 in which two methylene groups are replaced by oxygen.

                  3. A compound of Claim 1 in which two methylene groups are replaced by sulfur.

                  4. A compound of Claim 1 in which one methylene group is replaced with oxygen and another methylene group

is replaced by sulfur.

5. A compound of Claim 1 in which the fatty acid is a saturated C<sub>13</sub> or C<sub>14</sub> fatty acid.

6. A compound of Claim 1 in which the heteroatoms are separated by from 2 to 5 methylene groups.

7. 6,12-Dithiatetradecanoic acid or CH<sub>3</sub>CH<sub>2</sub>S(CH<sub>2</sub>)<sub>5</sub>S(CH<sub>2</sub>)<sub>4</sub>COOH.

10 8. 6,12-Dioxatetradecanoic acid or CH<sub>3</sub>CH<sub>2</sub>O(CH<sub>2</sub>)<sub>5</sub>O(CH<sub>2</sub>)<sub>4</sub>COOH.

9. 7,10-Dioxatetradecanoic acid or CH<sub>3</sub>(CH<sub>2</sub>)<sub>3</sub>O(CH<sub>2</sub>)<sub>2</sub>O(CH<sub>2</sub>)<sub>5</sub>COOH.

15 10. 9,12-Dioxatetradecanoic acid or CH<sub>3</sub>CH<sub>2</sub>O(CH<sub>2</sub>)<sub>2</sub>O(CH<sub>2</sub>)<sub>7</sub>COOH.

11. 9-Oxa,12-thiatetradecanoic acid or CH<sub>3</sub>CH<sub>2</sub>S(CH<sub>2</sub>)<sub>2</sub>O(CH<sub>2</sub>)<sub>7</sub>COOH.

12. 12-Oxa,9-thiatetradecanoic acid or CH<sub>3</sub>CH<sub>2</sub>O(CH<sub>2</sub>)<sub>2</sub>S(CH<sub>2</sub>)<sub>7</sub>COOH.

20 13. 10,13-Dioxatetradecanoic acid or CH<sub>3</sub>O(CH<sub>2</sub>)<sub>2</sub>O(CH<sub>2</sub>)<sub>8</sub>COOH.

14. 12-Oxa-6-thiatetradecanoic acid or CH<sub>3</sub>CH<sub>2</sub>O(CH<sub>2</sub>)<sub>5</sub>S(CH<sub>2</sub>)<sub>4</sub>COOH.

25 15. A method of acylating a peptide or protein comprising reacting the CoA ester of a compound of Claim 1 with said peptide or protein in the presence of N-myristoyltransferase.

30

35

40

45

50

55



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number

EP 91870022.0

| DOCUMENTS CONSIDERED TO BE RELEVANT   |  |                   |  |                 |                                  |          |        |            |          |
|---|--|-------------------|--|-----------------|----------------------------------|----------|--------|------------|----------|
| Category  | Citation of document with indication, where appropriate, of relevant passages  | Relevant to claim | CLASSIFICATION OF THE APPLICATION (Int. CL.5)  |                 |                                  |          |        |            |          |
| A   | EP - A1 - 0 327 523<br>(WASHINGTON UNIVERSITY)<br>* Claims *<br>--   | 1,15              | C 07 C 59/126<br>C 07 C 323/12<br>C 12 P 21/00 |                 |                                  |          |        |            |          |
| A   | DE - A1 - 3 135 946<br>(BAYER)<br>* Claim 1 *<br>--  | 1                 |  |                 |                                  |          |        |            |          |
| A   | CHEMICAL ABSTRACTS, vol. 106,<br>no. 25, June 22, 1987,<br>Columbus, Ohio, USA<br>D.A. TOWLER et al. "Amino-<br>terminal processing of<br>proteins, by N-myristoyla-<br>tion. Substrate specificity<br>of N-myristoyl transferase"<br>pages 294,295, abstract-No.<br>209 945p<br>& J. Biol. Chem. 1987, 263<br>(3), 1030-6<br>---- | 15                |  |                 |                                  |          |        |            |          |
| D   |  |                   | TECHNICAL FIELDS<br>SEARCHED (Int. CL.5)       |                 |                                  |          |        |            |          |
|   |  |                   | C 07 C 59/00<br>C 07 C 323/00<br>C 12 P 21/00  |                 |                                  |          |        |            |          |
| <p>The present search report has been drawn up for all claims</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">Place of search</td> <td style="width: 33%;">Date of completion of the search</td> <td style="width: 34%;">Examiner</td> </tr> <tr> <td>VIENNA</td> <td>02-05-1991</td> <td>HOPBAUER</td> </tr> </table>  |  |                   |  | Place of search | Date of completion of the search | Examiner | VIENNA | 02-05-1991 | HOPBAUER |
| Place of search   | Date of completion of the search   | Examiner          |  |                 |                                  |          |        |            |          |
| VIENNA  | 02-05-1991   | HOPBAUER          |  |                 |                                  |          |        |            |          |
| <p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone<br/>Y : particularly relevant if combined with another document of the same category<br/>A : technological background<br/>O : non-earlier disclosure<br/>P : intermediate document</p> <p>T : theory or principle underlying the invention<br/>E : earlier patent document, but published as, or after the filing date<br/>D : document cited in the application<br/>L : document cited for other reasons<br/>R : member of the same parent family, corresponding document</p> |  |                   |  |                 |                                  |          |        |            |          |